Form 4: Evommune CSO Executes Stock Option Exercise and Sale

Chief Scientific Officer Jeegar Patel exercised options for 13,512 shares and sold 16,687 shares of Evommune, Inc. common stock.

Summary

• Jeegar Patel, Chief Scientific Officer of Evommune, Inc., exercised stock options for 13,512 shares at a strike price of $3.84.
• Following the exercise, the reporting person sold 16,687 shares of common stock at a weighted average price of $22.74.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026.
• Post-transaction, the reporting person maintains beneficial ownership of 46,403 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents routine personal financial management by an executive.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
• The sale price of $22.74 represents a significant premium over the $3.84 exercise price.

Negatives

• The transaction results in a net reduction of the insider's direct equity stake in the company.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with best practices for corporate governance among publicly traded biotech firms.
• The spread between the exercise price and market price reflects typical equity compensation structures for C-suite executives in high-growth life sciences companies.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed through a pre-planned 10b5-1 arrangement.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Evommune, EVMN, Insider Trading, Form 4, Biotech, Stock Option Exercise